Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Efalizumab in Moderate to Severe Plaque Psoriasis
NCT00338143Phase 3Completed
- Sponsor
- Genentech
- Start
- Oct 2003
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 3 trial of efalizumab in plaque psoriasis, sponsored by Genentech. Started Oct 2003; status: completed.
02
Drugs
efalizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00338143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00338143.